Chemours (CC) Shares Jumped, What Is Behind The Latest Move?
Chemours (CC) is back in focus after agreeing to a multi party settlement with North Carolina and 11 nearby communities over PFAS and other emissions tied to its Fayetteville Works facility and related contamination issues.
The settlement headlines arrive after a choppy stretch for Chemours, with the share price at US$14.98 and a 1-day share price return of 3.10%. This sits against a 90-day share price return that declined 29.24% and a 1-year total shareholder return that declined 7.18%, hinting that recent legal clarity is drawing short-term interest while longer-term returns remain under pressure.
Scan how Chemours compares with other materials and chemicals players facing legal or environmental overhangs by reviewing the hand picked 30 resilient stocks with low risk scores that screen strongly on balance sheet resilience.
Chemours has jumped on the North Carolina settlement news, yet the share price is still well below past levels and screens at a sizeable implied discount. Is most of the rerating already behind it, or is the valuation gap still wide?
Most Popular Narrative: 24.3% Undervalued
Chemours is framed as undervalued in the most followed narrative, with a fair value of $19.78 against the latest close at $14.98. This sets up a valuation gap that hinges on how its refrigerants and advanced materials businesses play out.
Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher-value applications for APM. In addition, ongoing portfolio optimization and pricing improvements in these segments are structurally enhancing net margins and improving earnings quality. Renewed focus on manufacturing excellence and cost optimization, including ramped-up COE initiatives and strategic divestitures of underperforming product lines, is expected to deliver sustainable operating efficiencies, lower unit costs, and structurally higher net margins over the long term.
See why 12 investors see Chemours as 24% undervalued.
Result: Fair Value of $19.78 (UNDERVALUED)
Still, Chemours carries meaningful overhangs, with ongoing PFAS related liabilities and tighter environmental regulation both capable of squeezing profitability and cash generation if outcomes worsen.
Find out about the key risks to this Chemours narrative.
Next Steps
Sentiment around Chemours is mixed, with real concerns sitting beside genuine optimism. Consider acting while the legal dust is still settling and weigh both sides for yourself by reviewing the 4 key rewards and 2 important warning signs.
Looking for more Chemours sized investment ideas?
If Chemours has your attention, broaden your field of vision. The right screener can surface opportunities you would never spot by scrolling headlines alone.
- Target value first and stack the odds in your favor by scanning a curated set of underpriced quality stocks through the 29 high quality undervalued stocks.
- Prioritize resilience and sleep better at night by filtering for companies with strong finances using the list of solid balance sheet and fundamentals (23 results).
- Lock in potential income streams by reviewing established businesses with meaningful yields via the 7 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com